Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Qualyst Team on Hepatocyte Screening Services

NEW YORK (GenomeWeb News) – Invitrogen said yesterday that has signed a co-exclusive agreement with Qualyst to offer hepatocyte screening services and research products.
 
Invitrogen said that its wholly-owned subsidiary, CellzDirect, will provide in-house services and commercialized kits that combine Qualyst’s B-Clear technology with CellzDirect’s cell products, which include hepatocytes and products focused on drug metabolism and transport. Qualyst’s B-clear technology enables in vivo and in vitro prediction of hepatobiliary disposition, hepatic uptake, hepatic efflux, biliary clearance, and drug transport, the firms said.
 
The combination of the technologies “will create robust hepatocyte testing systems to help pharmaceutical companies avoid costly drug development challenges and expedite the development of safe and effective drugs,” Rob Brainin, vice president and general manager of CellzDirect, said in a statement.
 
The firms expect the new services to be available through Invitrogen in mid-December. Financial terms of the collaboration were not disclosed.
 
Invitrogen acquired CellzDirect for $57 million in cash in January.
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.